Text size Moderna’s headquarters in Cambridge, Massachusetts. Joseph Prezioso / AFP / Getty Images Moderna’s announcement of positive data about a Phase 1 trial of its Covid-19 vaccine in May was met with skepticism by some experts, who noted that the company had not included many details about the trial’s …
Read More »
Moderna Inc.’s shares soared in the extended session Tuesday after the biotech company said its coronavirus vaccine candidate produced a “robust” immune system response in a larger group of people and the study will go on to a decisive clinical trial in July. Results published in The New England Journal …
Read More »
Text size Joseph Prezioso / Getty Images Shares of Modern biotechnology fell 6.2% on Thursday afternoon after health news website Stat reported that the company was delaying the start of a Phase 3 trial of its experimental Covid-19 vaccine. The report, based on quotes from unidentified sources described as “investigators,” …
Read More »
Text size Daniel Acker / Bloomberg Shares of the large pharmaceutical company Pfizer continue to rise one day after the company revealed promising and detailed data on a trial of its experimental vaccine Covid-19. Analysts said the highly aggressive timeline the company outlined on Wednesday was exciting, but far from …
Read More »
Text size Dirk Waem / Getty Images NASH was once the next big thing for big drug companies; a newly defined disorder that requires chronic treatment that affects millions of people in developed countries. Dozens of companies are developing drugs for the disease, which can cause life-threatening conditions like decompensated …
Read More »